These ASX 200 shares could rise 25% to 30%

These shares are being tipped by analysts to rise very strongly from current levels.

Key points
  • James Hardie Industries, trading at an appealing valuation, is expected by Morgans to benefit from stabilising market conditions in North America, potentially offering over 25% upside with a price target of $35.50.
  • ResMed, a leader in sleep and respiratory care, provides strong investment potential with a 30% upside target from Macquarie, leveraging its recurring revenue model and digital health innovations for long-term growth.
  • Both companies are positioned for significant appreciation, supported by strategic strengths and current attractive pricing, offering compelling opportunities beyond typical market returns.

The Australian share market has delivered a return of approximately 10% per annum over the long term.

While that is a great return, investors don't necessarily have to settle for that.

Not when there are ASX 200 shares out there that analysts believe could deliver returns that are far greater than this.

With that in mind, let's take a look at two shares that could be dirt cheap right now:

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company

Image source: Getty Images

James Hardie Industries plc (ASX: JHX)

The first ASX 200 share that could offer material upside over the next 12 months is James Hardie.

This building products giant has been dealing with a tough demand environment in North America, as higher interest rates and softer housing activity weighed on volumes. Despite that, the company's most recent quarterly update signalled that conditions may be stabilising faster than expected.

This caught the eye of analysts at Morgans. They noted that while organic volumes are still declining, the performance was better than feared and could mark a bottoming in the cycle.

Morgans also estimates that James Hardie is now trading on a forward PE ratio of 17x, which it sees as undemanding given the company's strong market position and the potential for earnings to rebound as the US housing cycle improves.

In response to the update, the broker upgraded James Hardie shares to a buy rating with a $35.50 price target. Based on its current share price of $27.60, this implies potential upside of over 25% for investors.

ResMed Inc (ASX: RMD)

Another ASX 200 share that could rise strongly from current levels is ResMed.

The sleep and respiratory care giant helps millions of people manage sleep apnoea and related conditions. Its technology not only improves quality of life but also reduces healthcare costs, which is a powerful combination that has helped ResMed become a global leader in its field.

The company continues to grow thanks to its recurring revenue model, driven by the sale of masks, accessories, and cloud-connected devices. Its digital health platform, which monitors patient adherence, also provides valuable data that strengthens relationships with healthcare providers and insurers.

And after a period of share price weakness, the stock now looks very attractively priced. Macquarie, for example, has an outperform rating and $49.20 price target on its shares. Based on its current share price of $37.81, this implies potential upside of 30% for investors over the next 12 months.

But it isn't just about the next 12 months. Given its strong cash flow, robust balance sheet, and expanding pipeline of digital health innovations, ResMed could be a business to own for decades.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group and ResMed. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
Broker Notes

BHP, Westpac, CSL shares: Buy, sell, or hold?

One of these ASX shares is tipped to fall 13%.

Read more »

Woman tying up her shoelaces before a run.
Broker Notes

Buy, hold, sell: Coles, Wesfarmers, CSL shares

It's a new week and we've got new ratings from the experts.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Two male ASX investors and executives wearing dark coloured suits sit at a table holding their mobile phones discussing the highest trading ASX 200 shares today
Broker Notes

Buy, hold, sell: Resmed, Goodman Group, CBA shares

We review three fresh buy, hold, and sell calls from John Athanasiou at Red Leaf Securities.

Read more »

colleagues on a lunch break looking at iPhone
Broker Notes

Top brokers name 3 ASX shares to buy now

Here's what brokers are recommending as buys this week.

Read more »

Woman with her fingers crossed and eyes shut.
Broker Notes

7 ASX 200 shares in the buy zone as optimism returns to the market: experts

Brokers reaffirmed their buy calls on Liontown, Rio Tinto, Xero, and others this week.

Read more »

ASX shares broker ratings represented by three different coloured buttons.
Broker Notes

6 ASX shares upgraded and downgraded by the experts this week

Brokers have changed their ratings and 12-month price targets on Qantas, Codan, and others. 

Read more »

A woman sits in a cafe wearing a polka dotted shirt and holding a latte in one hand while reading something on a laptop that is sitting on the table in front of her
Broker Notes

Buy, hold, sell: CSL, NextDC, PLS shares

Mark Elzayed from Vestra Capital explains his ratings on three ASX 200 shares.

Read more »